___

• Joshi M, Sheikh H, Abbi K, Long S, Sharma K, Tulchinsky M, Epner E.
• Marginalzonelymphoma: old, new, targeted, andepigenetictherapies.
• TherAdvHematol2012;3:275-290.
• ZinzaniPL. Themanyfaces of marginalzonelymphoma.
• HematologyAmSocHematolEduc Program 2012;2012:426-432.
• Arcaini L, Paulli M, Boveri E, Magrini U, Lazzarino M. Marginalzone-related
• neoplasms of splenicandnodalorigin. Haematologica 2003;88:80-93.
• Iannitto E, Ambrosetti A, Ammatuna E, Colosio M, Florena AM, Tripodo
• C, et al. Splenicmarginalzonelymphomawithorwithoutvillouslymphocyt
• es. Hematologic indingsandoutcomes in a series of 57 patients. Cancer
• ;101:2050-2057.
• Parry-Jones N, Matutes E, Gruszka-Westwood AM, SwansburyGJ,
• WotherspoonAC, Catovsky D. Prognosticfeatures of spleniclymphomawith
• villouslymphocytes: a report on 129 patients. Br J Haematol 2003;120:759-
• -
• Franco V, Florena AM, Iannitto E. Splenicmarginalzonelymphoma. Blood
• ;101:2464-2472.
• Thieblemont C, Felman P, Berger F, Dumontet C, Arnaud P, Hequet O, et
• al. Treatment of splenicmarginalzone B-celllymphoma: an analysis of 81
• patients. ClinLymphoma 2002;3:41-47.
• Salido M, Baro C, Oscier D, Stamatopoulos K, Dierlamm J, Matutes E, et
• al. Cytogenetic aberrationsandtheirprognosticvalue in a series of 330
• splenicmarginalzone B-celllymphomas: a multicenterstudy of theSplenic
• B-Cell LymphomaGroup. Blood 2010;116:1479-1488.
• Boveri E, Arcaini L, Merli M, Passamonti F, Rizzi S, Vanelli L, et al. Bone
• marrow histology in marginalzone B-celllymphomas: correlationwithclinic
• alparameters andflowcytometry in 120 patients. AnnOncol 2009;20:129-
• -
• Berger F, Felman P, Thieblemont C, Pradier T, Baseggio L, BryonPA,
• et al. Non- MALT marginalzone B-celllymphomas: a description of
• clinicalpresentationand outcome in 124 patients. Blood 2000;95:1950-
• -
• Kaynaklar